<DOC>
	<DOCNO>NCT00483717</DOCNO>
	<brief_summary>The study evaluate efficacy safety use ketorolac nasal spray acute treatment migraine .</brief_summary>
	<brief_title>Efficacy Safety Intranasal Ketorolac Acute Treatment Migraine</brief_title>
	<detailed_description>Evaluates efficacy safety use ketorolac nasal spray acute treatment migraine .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Diagnosis migraine without aura ( IHS criterion 1.1 1.2.1 ) ; Onset migraine prior age 50 ; 28 moderate severe migraine headache per month Subjects receive investigational drug within 30 day study entry ; More 15 headache day per month ; Known allergy hypersensitivity ketorolac and/or excipients ; Allergy aspirin NSAIDs ; Currently receive NSAIDs aspirin ; Medical history would preclude NSAID use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Ketorolac</keyword>
</DOC>